Double-blind RCTs on Magnesium Bisglycinate NMDA/GABA receptor modulation and nocturnal cortisol reduction, antidepressant remission meta-analyses, SAMe augmentation trials, and optical smartwatch HRV validation studies. Explore 674 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
At Week 10, the differences of brexpiprazole 1 and 2 mg versus placebo for NPI total score were -1.2 (p = 0.5891) and -8.4 (p < 0.0001), and those for NPI-Distress total score were -1.1 (p = 0.2292) and -3.9 (p < 0.0001),...
We present a large cohort of FAB scores in the SPMS population.
Future research needs to determine whether the addition of biomarkers to clinical and sociodemographic variables can improve model accuracy in predicting full symptom relief of pharmacologically-treated psychotic depression.
Of the 451 patients from SAMMPRIS, 378 met inclusion criteria.
Mapping from data-driven symptom improvement onto neural circuits revealed treatment-responsive neural profiles that may aid in optimal patient selection for future trials.
Establishing an MCID strengthens the SI-VAS value, adds context for findings related to sleep inertia in individuals with idiopathic hypersomnia from the phase 3 study, and aids clinicians in identifying clinically meaningful...
64.6% for Bupropion), the combination's safety profile remained comparable, with no significant increase in treatment discontinuation.
While both techniques induce important changes in the WM microstructure, HA-PCI might better preserve the topological organization of brain networks than PCI.
High-dose aducanumab demonstrated clinically meaningful slowing of progression across clinical endpoints measuring cognition, daily function, and behavioral symptoms.
These data suggest that plasma GFAP is a relapse-independent metric of baseline disease severity and a predictor of treatment response in participants with RMS.
443 individuals expressed interest within eight months; 50 met the criteria for enrollment.
This meta-analysis highlights the critical role of sleep disorders in dementia risk, emphasizing the need for early detection and management of sleep disturbances.
Further long-term studies are needed to draw definitive conclusions regarding the real-world benefits and safety of combination therapy with antidepressants and Z-drugs.
We included 8,071 Enroll-HD participants (mean baseline age: 51.4 years, 51.5% female) to develop a natural history progression model using baseline characteristics as predictive covariates.
Taken together, reduced baseline AEA and cortisol levels emerge as robust biomarker in depressed youth, while the negative longitudinal association between hair cortisol and depression symptoms might provide useful for therapy...
Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs.
In both trial extensions, NPAEs persisted in 3%-4% of participants 96 weeks after switching to a DOR-based regimen, possibly representing the background rate for these events.
Sex was an effect.
Purine-related metabolites were decreased across all arms.
Elinzanetant reduces the frequency and intensity of VMS and enhances quality of life and sleep quality in patients with menopause-related symptoms.
Soft tissue surgery for OSA treatment in adults significantly resulted in long-term blood pressure reduction.
Cumulative changes in mood states observed with repeated infusions suggest that propofol engages adaptive mechanisms in mood circuitry.
In this study anesthesia-induced oscillations were associated with postoperative outcomes; however, these were not independently associated with delirium or discharge disposition after considering preoperative cognitive and...
LEM treatment benefited subjects with trouble sleeping treated with medications for depression/anxiety symptoms, with no new safety signals.
LEM significantly increased TST in participants with trouble sleeping and mild OSA.
In 363 adult patients (225 from EMBARC and 138 from CANBIND-1; mean [SD] age, 36.6 [13.1] years; 235 women [64.7%]), the best-performing models using pretreatment clinical features and functional connectivity of the dorsal...
The probabilities of agomelatine having the highest full symptom relief rate and lowest discontinuation (due to AEs) rate were 67% and 68%, respectively.
The risk-benefit profile of tenecteplase thrombolysis was preserved in the older adults patients, which lends further support to intravenous 0.25 mg/kg tenecteplase as an alternative to alteplase in these patients.
Findings related to obstructive sleep apnea syndrome were mixed.
Esketamine nasal spray consistently demonstrated significant superiority over quetiapine extended release using all pre-specified definitions for full symptom relief and relapse.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
